Heterozygous expression of the oncogenic Pik3caH1047R mutation during murine development results in fatal embryonic and extraembryonic defects

Developmental Biology

Volumn 404, Issue 1, 2015, Pages 14-26

  Hare, Lauren M ^a,b   Schwarz, Quenten ^c   Wiszniak, Sophie ^c   Gurung, Rajendra ^b   Montgomery, Karen G ^a   Mitchell, Christina A ^b   Phillips, Wayne A ^a,b,d  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Angiogenesis; Cardiovascular system; Development; Embryogenesis; PI3K; Pik3ca

Indexed keywords

ANGIOPOIETIN RECEPTOR; CRE RECOMBINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P110; PIK3CA PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; EMBRYO; EMBRYO DEATH; EMBRYO DEVELOPMENT; EMBRYO MEMBRANE; EMBRYONAL TISSUE; ENDOTHELIUM CELL; ENZYME ACTIVE SITE; FATALITY; GENE; GENE EXPRESSION; GENE TARGETING; GERM LINE; INHERITANCE; LETHALITY; MOUSE; MOUSE MODEL; NONHUMAN; PIK3CA GENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; SOMATIC MUTATION; VASCULAR REMODELING; ANIMAL; ANIMAL EMBRYO; CARDIOVASCULAR MALFORMATION; GENETICS; HETEROZYGOTE; LETHAL GENE; METABOLISM; MUTATION;

MURINAE;

ANIMALS; CARDIOVASCULAR ABNORMALITIES; EMBRYO, MAMMALIAN; ENDOTHELIAL CELLS; GENE KNOCK-IN TECHNIQUES; GENES, LETHAL; HETEROZYGOTE; MICE; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES;

EID: 84931573300     PISSN: 00121606     EISSN: 1095564X     Source Type: Journal    
DOI: 10.1016/j.ydbio.2015.04.022     Document Type: Article

References (41)

1. Bi L., Okabe I., Bernard D.J., Wynshaw-Boris A., Nussbaum R.L. Proliferative Defect and Embryonic Lethality in Mice Homozygous for a Deletion in the p110α Subunit of Phosphoinositide 3-Kinase. J. Biol. Chem. 1999, 274(16):10963-10968.
2. Chalhoub N., Baker S.J. PTEN and the PI3-Kinase Pathway in Cancer. Annu. Rev. Pathol. 2009, 4:127-150.
3. Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., Fahrig M., Vandenhoeck A., Harpal K., Eberhardt C., Declercq C., Pawling J., Moons L., Collen D., Risau W., Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996, 380(6573):435-439.
4. Dummler B., Tschopp O., Hynx D., Yang Z.Z., Dirnhofer S., Hemmings B.A. Life with a single isoform of Akt: mice lacking Akt2 and Akt3 are viable but display impaired glucose homeostasis and growth deficiencies. Mol. Cell. Biol. 2006, 26(21):8042-8051.
5. Di Cristofano A., Pesce B., Cordon-Cardo C., Pandolfi P.P. Pten is essential for embryonic development and tumour suppression. Nat. Genet. 1998, 19(4):348-355.
6. Drake C.J., Little C.D. Exogenous vascular endothelial growth factor induces malformed and hyperfused vessels during embryonic neovascularization. Proc. Natl. Acad. Sci. USA 1995, 92(17):7657-7661.
7. Dvorak H.F., Orenstein N.S., Carvalho A.C., Churchill W.H., Dvorak A.M., Galli S.J., Feder J., Bitzer A.M., Rypysc J., Giovinco P. Induction of a fibrin-gel investment: an early event in hepatocarcinoma growth mediated by tumor-secreted products. J. Immunol. 1979, 122(1):166-174.
8. Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'Shea K.S., Powell-Braxton L., Hillan K.J., Moore M.W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996, 380(6573):439-442.
9. Graupera M., Guillermet-Guibert J., Foukas L.C., Phng L.K., Cain R.J., Salpekar A., Pearce W., Meek S., Millan J., Cutillas P.R., Smith A.J., Ridley A.J., Ruhrberg C., Gerhardt H., Vanhaesebroeck B. Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration. Nature 2008, 453(7195):662-666.
10. Garcia M.D., Larina Vascular development and hemodynamic force in the mouse yolk sac. Front. Physiol. 2014, 5:308.
11. Hamada K., Sasaki T., Koni P.A., Natsui M., Kishimoto H., Sasaki J., Yajima N., Horie Y., Hasegawa G., Naito M., Miyazaki J., Suda T., Itoh H., Nakao K., Mak T.W., Nakano T., Suzuki A. The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev. 2005, 19(17):2054-2065.
12. Hare L.M., Phesse T.J., Waring P.M., Montgomery K.G., Kinross K.M., Mills K., Roh V., Heath J.K., Ramsay R.G., Ernst M., Phillips W.A. Physiological expression of the PI3K-activating mutation Pik3caH1047R combines with Apc loss to promote development of invasive intestinal adenocarcinomas in mice. Biochem. J. 2014, 458(2):251-258.
13. Isakoff S.J., Engelman J.A., Irie H.Y., Luo J., Brachmann S.M., Pearline R.V., Cantley L.C., Brugge J.S. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 2005, 65(23):10992-11000.
14. Kurek K., Luks V., Ayturk U., Alomari A., Fishman S., Spencer S., Mulliken J., Bowen M., Yamamoto G., Kozakewich H., Warman M. Somatic Mosaic Activating Mutations in PIK3CA Cause CLOVES Syndrome. Am. J. Hum. Genet. 2012, 90(6):1108-1115.
15. Kinross K.M., Montgomery K.G., Kleinschmidt M., Waring P., Ivetac I., Tikoo A., Saad M., Hare L., Roh V., Mantamadiotis T., Sheppard K.E., Ryland G.L., Campbell I.G., Gorringe K.L., Christensen J.G., Cullinane C., Hicks R.J., Pearson R.B., Johnstone R.W., McArthur G.A., Phillips W.A. An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J. Clin. Investig. 2012, 122(2):553-557.
16. Kisanuki Y.Y., Hammer R.E., Miyazaki J., Williams S.C., Richardson J.A., Yanagisawa M. Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. Dev. Biol. 2001, 230(2):230-242.
17. Keppler-Noreuil K.M., Sapp J.C., Lindhurst M.J., Parker V.E., Blumhorst C., Darling T., Tosi L.L., Huson S.M., Whitehouse R.W., Jakkula E., Grant I., Balasubramanian M., Chandler K.E., Fraser J.L., Gucev Z., Crow Y.J., Brennan L.M., Clark R., Sellars E.A., Pena L.D., Krishnamurty V., Shuen A., Braverman N., Cunningham M.L., Sutton V.R., Tasic V., Graham J.M., Geer J., Henderson A., Semple R.K., Biesecker L.G. Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum. Am. J. Med. Genet. Part A 2014, 164A(7):1713-1733.
18. Lee J.H., Huynh M., Silhavy J.L., Kim S., Dixon-Salazar T., Heiberg A., Scott E., Bafna V., Hill K.J., Collazo A., Funari V., Russ C., Gabriel S.B., Mathern G.W., Gleeson J.G. De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. Nat. Genet. 2012, 44(8):941-945.
19. Lindhurst M.J., Parker V.E.R., Payne F., Sapp J.C., Rudge S., Harris J., Witkowski A.M., Zhang Q., Groeneveld M.P., Scott C.E., Daly A., Huson S.M., Tosi L.L., Cunningham M.L., Darling T.N., Geer J., Gucev Z., Sutton V.R., Tziotzios C., Dixon A.K., Helliwell T., O'Rahilly S., Savage D.B., Wakelam M.J.O., Barroso I., Biesecker L.G., Semple R.K. Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. Nat. Genet. 2012, 44(8):928-933.
20. Lelievre E., Bourbon P.M., Duan L.J., Nussbaum R.L., Fong G.H. Deficiency in the p110alpha subunit of PI3K results in diminished Tie2 expression and Tie2(-/-)-like vascular defects in mice. Blood 2005, 105(10):3935-3938.
21. Layton M.J., Saad M., Church N.L., Pearson R.B., Mitchell C.A., Phillips W.A. Autophosphorylation of serine 608 in the p85 regulatory subunit of wild type or cancer-associated mutants of phosphoinositide 3-kinase does not affect its lipid kinase activity. BMC Biochem. 2012, 13:30.
22. Martinez-Gac L., Alvarez B., Garcia Z., Marques M., Arrizabalaga M., Carrera A.C. Phosphoinositide 3-kinase and Forkhead, a switch for cell division. Biochem. Soc. Trans. 2004, 32(Pt 2):360-361.
23. Miquerol L., Langille B.L., Nagy A. Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression. Development 2000, 127(18):3941-3946.
24. Recovery and in vitro culture of pre-implantation-stage embryos. Manipulating the Mouse Embryo: A Laboratory Manual (Third Edition) 2003, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York. A. Nagy, M. Gertsenstein, K. Vintersten, R. Behringer (Eds.).
25. Isolation, culture, and manipulation of post-implantation embryos. Manipulating the Mouse Embryo: A Laboratory Manual (Third Edition) 2003, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York. A. Nagy, M. Gertsenstein, K. Vintersten, R. Behringer (Eds.).
26. Orloff Mohammed S., He X., Peterson C., Chen F., Chen J.-L., Mester Jessica L., Eng C. Germline PIK3CA and AKT1 Mutations in Cowden and Cowden-like Syndromes. Am. J. Hum. Genet. 2013, 92(1):76-80.
27. Olsson A.K., Dimberg A., Kreuger J., Claesson-Welsh L. VEGF receptor signalling-in control of vascular function. Nat. Rev. Mol. Cell Biol. 2006, 7(5):359-371.
28. Riviere J.B., Mirzaa G.M., O'Roak B.J., Beddaoui M., Alcantara D., Conway R.L., St-Onge J., Schwartzentruber J.A., Gripp K.W., Nikkel S.M., Worthylake T., Sullivan C.T., Ward T.R., Butler H.E., Kramer N.A., Albrecht B., Armour C.M., Armstrong L., Caluseriu O., Cytrynbaum C., Drolet B.A., Innes A.M., Lauzon J.L., Lin A.E., Mancini G.M., Meschino W.S., Reggin J.D., Saggar A.K., Lerman-Sagie T., Uyanik G., Weksberg R., Zirn B., Beaulieu C.L., Finding of Rare Disease Genes (FORGE) Canada Consortium, Majewski J., Bulman D.E., O'Driscoll M., Shendure J., Graham J.M., Boycott K.M., Dobyns W.B. De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nat. Genet. 2012, 44(8):934-940.
29. Samuels Y., Waldman T. Oncogenic mutations of PIK3CA in human cancers. Curr. Top. Microbiol. Immunol. 2010, 347:21-41.
30. Schwenk F., Baron U., Rajewsky K. A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. Nucleic Acids Res. 1995, 23(24):5080-5081.
31. Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat. Genet. 1999, 21:70-71.
32. Samuels Y., Diaz L.A., Schmidt-Kittler O., Cummins J.M., Delong L., Cheong I., Rago C., Huso D.L., Lengauer C., Kinzler K.W., Vogelstein B., Velculescu V.E. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005, 7(6):561-573.
33. Schwarz Q., Maden C.H., Vieira J.M., Ruhrberg C. Neuropilin 1 signaling guides neural crest cells to coordinate pathway choice with cell specification. Proc. Natl. Acad. Sci. USA 2009, 106(15):6164-6169.
34. Schwarz Q., Ruhrberg C. Neuropilin, you gotta let me know: should I stay or should I go?. Cell Adhes. Migr. 2010, 4(1):61-66.
35. Saal L.H., Holm K., Maurer M., Memeo L., Su T., Wang X., Yu J.S., Malmstrom P.O., Mansukhani M., Enoksson J., Hibshoosh H., Borg A., Parsons R. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 2005, 65(7):2554-2559.
36. H1047R Mutation in the Mouse Mammary Gland Results in Ductal Hyperplasia and Formation of ERα-Positive Tumors. PLoS One 2012, 7(5):e36924.
37. Takahashi T., Takahashi K., John P.L., Fleming P.A., Tomemori T., Watanabe T., Abrahamson D.R., Drake C.J., Shirasawa T., Daniel T.O. A mutant receptor tyrosine phosphatase, CD148, causes defects in vascular development. Mol. Cell. Biol. 2003, 23(5):1817-1831.
38. Tanaka Y., Kanai F., Tada M., Asaoka Y., Guleng B., Jazag A., Ohta M., Ikenoue T., Tateishi K., Obi S., Kawabe T., Yokosuka O., Omata M. Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients. Oncogene 2006, 25(20):2950-2952.
39. Vanhaesebroeck B., Stephens L., Hawkins P. PI3K signalling: the path to discovery and understanding. Nat. Rev. Mol. Cell Biol. 2012, 13(3):195-203.
40. Yang Z.Z., Tschopp O., Di-Poi N., Bruder E., Baudry A., Dummler B., Wahli W., Hemmings B.A. Dosage-dependent effects of Akt1/protein kinase Bα (PKBα) and Akt3/PKBγ on thymus, skin, and cardiovascular and nervous system development in mice. Mol. Cell. Biol. 2005, 25(23):10407-10418.
41. Zardavas D., Phillips W.A., Loi S. PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data. Breast Cancer Res. 2014, 16(1):201.